Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

361.87USD
15 Aug 2018
Change (% chg)

$-4.36 (-1.19%)
Prev Close
$366.23
Open
$365.00
Day's High
$368.82
Day's Low
$361.20
Volume
216,839
Avg. Vol
315,588
52-wk High
$505.00
52-wk Low
$281.89

Select another date:

Mon, Aug 6 2018

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.

Regeneron posts quarterly profit beat, strongly backs Eylea's future

Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.

Regeneron profit beats expectations on sales of eczema drug

Aug 2 Drugmaker Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit, helped by higher sales of eczema drug Dupixent.

Regeneron's newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.

UPDATE 3-Regeneron's newer drugs disappoint, shares slip

* Shares down 2 pct (Adds background, comments from conf. call and analyst, updates shares)

BRIEF-Regeneron Reports Q1 GAAP Earnings Per Share $4.16

* REGENERON REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

Regeneron's first quarter profit soars 92 percent

May 3 Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

Select another date: